Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Research Highlight
  • Published:

HEART FAILURE

Empagliflozin improves clinical outcomes for HFpEF in EMPEROR-Preserved

Nature Reviews Cardiology volume 18, page 737 (2021)Cite this article

Subjects

The sodium–glucose cotransporter 2 (SGLT2) inhibitor empagliflozin reduces the risk of the composite of cardiovascular death or hospitalization for heart failure (HF) in patients with HF with preserved ejection fraction (HFpEF) compared with placebo, according to the EMPEROR-Preserved phase III trial. This finding, presented at the ESC Congress 2021 and simultaneously published in the New England Journal of Medicine, establishes empagliflozin as the first and only drug therapy to significantly improve outcomes for the full spectrum of patients with HF.

The EMPEROR-Preserved trial was a randomized, double-blind, placebo-controlled study that recruited patients with functional class II–IV chronic HF and left ventricular ejection fraction >40%. The primary outcome was a composite of adjudicated cardiovascular death or hospitalization for HF.

This is a preview of subscription content, access via your institution

Relevant articles

Open Access articles citing this article.

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

References

Original articles

Related articles

  • Mishra, S. et al. Cellular and molecular pathobiology of heart failure with preserved ejection fraction. Nat. Rev. Cardiol. 18, 400–423 (2021)

    Article  Google Scholar 

  • Cowie, M. R. et al. SGLT2 inhibitors: mechanisms of cardiovascular benefit beyond glycaemic control. Nat. Rev. Cardiol. 17, 761–772 (2020)

    Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Nature Reviews Cardiology http://www.nature.com/nrcardio/

    Karina Huynh

Authors
  1. Karina Huynh
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Karina Huynh.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Huynh, K. Empagliflozin improves clinical outcomes for HFpEF in EMPEROR-Preserved. Nat Rev Cardiol 18, 737 (2021). https://doi.org/10.1038/s41569-021-00627-z

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/s41569-021-00627-z

This article is cited by

Search

Advanced search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing